366 related articles for article (PubMed ID: 33064892)
1. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
5. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
6. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
8. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
[TBL] [Abstract][Full Text] [Related]
10. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
[TBL] [Abstract][Full Text] [Related]
12. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
13. Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
Dabal TD; Haltom MB; Patel PP; Son CK; Joglekar KP; Groeschell CM; Chumpia MM; Kamal SF; Seth A; Jackson CD
South Med J; 2021 May; 114(5):288-292. PubMed ID: 33942113
[TBL] [Abstract][Full Text] [Related]
14. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice.
González-Freire L; Giménez-Candela RM; Castro-Luaces S; Veiga-Villaverde AB; Crespo-Diz C
Farm Hosp; 2021 Jun; 45(4):165-169. PubMed ID: 34218760
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
19. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
20. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
